Lepu Biopharma Co Ltd

02157

Company Profile

  • Business description

    Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.

  • Contact

    Lianheng Road, Block 4
    No. 651, Minhang District
    Shanghai201112
    CHN

    T: +86 2167680899

    https://www.lepubiopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    710

Stocks News & Analysis

stocks

Chart of the Week: What 650 IPOs reveal about long-term performance

Our data shows buying into the IPO hype can be costly.
stocks

Cheap ASX telco with plenty of upside

Why the market may have overlooked this ASX top pick.
stocks

Avoid this overvalued ASX lithium producer

Why the market may be overpricing future earnings for this lithium producer.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,951.6054.00-0.60%
CAC 408,431.6146.120.55%
DAX 4025,000.54260.181.05%
Dow JONES (US)52,242.05393.150.76%
FTSE 10010,529.8968.260.65%
HKSE23,076.91335.27-1.43%
NASDAQ25,380.5196.13-0.38%
Nikkei 22572,366.343,191.384.61%
NZX 50 Index13,493.0592.390.69%
S&P 5007,372.8714.650.20%
S&P/ASX 2008,748.7051.90-0.59%
SSE Composite Index4,120.289.470.23%

Market Movers